All publications

Export 33 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Male  [Clear All Filters]
Mbisa JL, Fearnhill E, Dunn D, Pillay D, Asboe D, Cane P A.  2015.  Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom. Clin Infect Dis. 61:829-36.
Takebe Y., Naito Y., Raghwani J., Fearnhill E, Sano T., Kusagawa S., Mbisa JL, Zhang H, Matano T., Leigh Brown A.J et al..  2014.  Intercontinental dispersal of HIV-1 subtype B associated with transmission among men who have sex with men in Japan. J Virol. 88:9864-76.
Hué S, Brown A.E, Ragonnet-Cronin M, Lycett SJ, Dunn D, Fearnhill E, Dolling D, Pozniak A, Pillay D, Delpech V et al..  2014.  Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions. AIDS. 28:1967-75.
Hodcroft EB, Hadfield J, Fearnhill E, Phillips A, Dunn D, O’Shea S, Pillay D, Leigh Brown A.J.  2014.  The contribution of viral genotype to plasma viral set-point in HIV infection. PLoS Pathog. 10:e1004112.
UK HIV Drug Resistance Database.  2014.  The increasing genetic diversity of HIV-1 in the UK, 2002-2010. AIDS. 28:773-80.
Bulteel N, Bansi-Matharu L., Churchill D, Dunn D, Bibby D., Hill T, Sabin C, Nelson M.  2014.  The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect. 68:77-84.
Foster GM, Ambrose JC, Hué S, Delpech V, Fearnhill E, Abecasis AB, Leigh Brown A.J, Geretti A M.  2014.  Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of Circulating Recombinant Form (CRF) 50_A1D. PLoS One. 9:e83337.
Castro H, Pillay D, Cane P A, Asboe D, Cambiano V, Phillips A, Dunn D.  2013.  Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 208:1459-63.
Dolling D, Dunn D, Sutherland K.A, Pillay D, Mbisa JL, Parry C.M, Post FA, Sabin C, Cane P A.  2013.  Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother. 68:2339-43.
Santoro MM, Sabin C, Forbici F., Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E., Antinori AM, Palamara G et al..  2013.  Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Med. 14:571-7.
Mackie NE, Dunn D, Dolling D, Garvey L, Harrison LJ, Fearnhill E, Tilston P, Sabin C, Geretti A M.  2013.  The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 27:2245-53.
De Luca A., Dunn D, Zazzi M, Camacho R., Torti C., Fanti I., Kaiser R., Sonnerborg A., Codoner F.M, Van Laethem K. et al..  2013.  Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207:1216-20.
Waters L., Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D, Phillips A.  2013.  Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Antivir Ther. 18:213-9.
Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Leigh Brown A.J, Churchill D, Williams I, Geretti A M et al..  2012.  Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ. 345:e5253.
Dolling D, Phillips A, Delpech V, Pillay D, Cane P A, Crook A.M, Shepherd J., Fearnhill E, Hill T, Dunn D.  2012.  Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med. 13:309-14.
Barber TJ, Harrison LJ, Asboe D, Williams I, Kirk S., Gilson R, Bansi L, Pillay D, Dunn D.  2012.  Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 67:995-1000.
Leigh Brown A.J, Lycett SJ, Weinert L, Hughes GJ, Fearnhill E, Dunn D.  2011.  Transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis. 204:1463-9.
Wittkop L., Gunthard H.F, de Wolf F., Dunn D, Cozzi-Lepri A, De Luca A., Kucherer C., Obel N., von Wyl V., Masquelier B. et al..  2011.  Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 11:363-71.
Bansi L, Smith C, Phillips A, Kirk S., Geretti A M, Johnson M, Mackie NE, Post FA, Gazzard B, Dunn D et al..  2011.  The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.
Prosperi M.C, Mackie NE, Di Giambenedetto S., Zazzi M, Camacho R., Fanti I., Torti C., Sonnerborg A., Kaiser R., Codoner F.M et al..  2011.  Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66:1886-96.